Immutep's Abstract On IMP761 Accepted For Poster Presentation At ACR Convergence 2026

Benzinga · 1d ago

• Late-breaking poster will present data from the first-in-human Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, in healthy volunteers